TD Cowen Starts Alamar Biosciences (ALMR) at Buy

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $30.00.

The analyst comments "We initiate on ALMR at Buy w/a $30 PT (26% upside). Its NULISA chemistry & easy-to-use, robust Argo platform offer a one-two combo that is generating material enthusiasm at leading Pharma and A&G proteomics customers. NULISA is ultra-sensitive & can scale from 1 protein into the 100s, enabling use across R&D & diagnostics. Sales are set to more than double ('25 to '27) & grow at a 40% CAGR to '30."

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click here.

Shares of Alamar Biosciences closed at $23.88 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Alamar Biosciences (ALMR) PT Raised to $32 at Stifel